STOCK TITAN
  1. Home
  2. SEC Filings
  3. MRNA
  4. [144] Moderna, Inc. SEC Filing

Moderna officer plans $4.7M stock sale in 2026

Available on EDGAR Accepted by SEC EDGAR
Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
144

Rhea-AI Filing Summary

Moderna, Inc. (MRNA) received a Rule 144 notice that officer James M. Mock, through Fidelity Brokerage Services LLC, plans to sell up to 34,836 shares of common stock, with an indicated aggregate market value of $4,685,093.64, beginning on or about September 10, 2026.

The shares derive from multiple restricted stock vesting events between October 5, 2023 and May 28, 2025 and a planned stock option exercise of 19,836 shares for cash on September 10, 2026. Common shares outstanding are stated as 399,235,889.

Shares to be sold under Rule 144 34,836 shares Planned sale of Moderna common stock for account of James M. Mock
Aggregate market value of shares to be sold $4,685,093.64 Value reported for the 34,836 Moderna shares covered by the notice
Common shares outstanding 399,235,889 shares Moderna common stock outstanding figure provided alongside the sale notice
Stock option exercise shares 19,836 shares Shares to be acquired via stock option exercise for cash on September 10, 2026
Restricted stock vesting on October 5, 2023 2,952 shares Compensation-related restricted stock vesting from issuer on October 5, 2023
Restricted stock vesting on February 27, 2025 2,966 shares Compensation-related restricted stock vesting from issuer on February 27, 2025
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Vesting financial
"Common | 10/05/2023 | Restricted Stock Vesting | Issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
Stock Option Exercise financial
"Common | 09/10/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
attorney-in-fact regulatory
"as attorney-in-fact for James Mock"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Moderna, Inc. (MRNA)?
It discloses that officer James M. Mock, through Fidelity Brokerage Services LLC, plans to sell up to 34,836 shares of Moderna common stock under Rule 144, with an indicated aggregate market value of $4,685,093.64, starting around September 10, 2026.

How many Moderna (MRNA) shares are planned to be sold and what is their value?
The notice covers up to 34,836 shares of Moderna common stock, with an indicated aggregate market value of $4,685,093.64. These figures are reported in the securities information section for the planned Rule 144 sale.

Who is selling Moderna (MRNA) shares in this Form 144 and through which broker?
The planned sale is for the account of James M. Mock, an officer of Moderna, Inc. The securities are held and the filing is executed through Fidelity Brokerage Services LLC, which signed the notice as attorney-in-fact for James M. Mock.

What is the source of the Moderna (MRNA) shares to be sold under Rule 144?
The shares come from multiple restricted stock vesting awards between October 5, 2023 and May 28, 2025, and from a planned stock option exercise of 19,836 shares for cash on September 10, 2026, all issued by Moderna as compensation.

What percentage of Moderna (MRNA) outstanding shares does this Form 144 sale represent?
The notice states 399,235,889 Moderna common shares outstanding and up to 34,836 shares to be sold. The filing does not calculate a percentage, but both figures are disclosed for context in the securities information section.

When is the planned sale date for the Moderna (MRNA) shares under this Form 144?
The planned sale date is listed as September 10, 2026. That date appears in the securities information section and also as the date of a related stock option exercise for 19,836 shares for cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR

Keep reading

More on MRNA

All MRNA news

Trending in the feed

DDD
3D Systems Announces Agreements to Exchange All Outstanding 5.875% Convertible Senior Secured Notes Due 2030, Eliminating All Secured Debt Open the live feed